Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jesús Fuentes-Antras"'
Autor:
Kissy Guevara-Hoyer, Jesús Fuentes-Antrás, Eduardo de la Fuente-Muñoz, Miguel Fernández-Arquero, Fernando Solano, Pedro Pérez-Segura, Esmeralda Neves, Alberto Ocaña, Rebeca Pérez de Diego, Silvia Sánchez-Ramón
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Common variable immunodeficiency (CVID) represents the largest group of primary immunodeficiencies that may manifest with infections, inflammation, autoimmunity, and cancer, mainly B-cell non-Hodgkin’s lymphoma (NHL). Indeed, NHL may result from ch
Externí odkaz:
https://doaj.org/article/2718f588ad8a45d9b1561b440fdc8138
Autor:
Jesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, Igor López-Cade, Víctor Lorca, Alejandro Pascual, Alicia de Luna, Carmen Ramírez-Ruda, Jennifer Swindell, Paloma Flores, Ana Lluch, David W. Cescon, Pedro Pérez-Segura, Alberto Ocaña, Frederick Jones, Fernando Moreno, Vanesa García-Barberán, José Ángel García-Sáenz
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11419 (2023)
Endocrine-resistant, hormone receptor-positive, and HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is largely governed by acquired mutations in the estrogen receptor, which promote ligand-independent activation, and by truncal alterations i
Externí odkaz:
https://doaj.org/article/ad6deb7e9e48410696732803de1a58c1
Autor:
Jesús Fuentes-Antrás, Alicia de Luna, Alfonso López de Sá, Alberto Ocaña, José Ángel García-Sáenz, Fernando Moreno
Publikováno v:
Breast, Vol 54, Iss , Pp 160-163 (2020)
Cyclin-dependent kinase inhibitors (CDKIs) and endocrine therapy (ET) are the corner-stone of systemic therapy for patients with hormone-positive (HR+) HER2-negative metastatic breast cancer (MBC). However, limited data exist regarding rechallenge tr
Externí odkaz:
https://doaj.org/article/95698fb758b5427f9c6c094f9ae51f0a
Autor:
Jesús Fuentes-Antrás, Kissy Guevara-Hoyer, Mariona Baliu-Piqué, José Ángel García-Sáenz, Pedro Pérez-Segura, Atanasio Pandiella, Alberto Ocaña
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Immunotherapy has become a cornerstone in the treatment of cancer and changed the way clinicians and researchers approach tumor vulnerabilities. Durable responses are commonly observed with immune checkpoint inhibitors in highly immunogenic tumors, w
Externí odkaz:
https://doaj.org/article/6f092a0bc5c94891bb7808bada045331
Autor:
Kissy Guevara-Hoyer, Jesús Fuentes-Antrás, Eduardo De la Fuente-Muñoz, Antonia Rodríguez de la Peña, Marcos Viñuela, Noemí Cabello-Clotet, Vicente Estrada, Esther Culebras, Alberto Delgado-Iribarren, Mercedes Martínez-Novillo, Maria José Torrejón, Rebeca Pérez de Diego, Miguel Fernández-Arquero, Alberto Ocaña, Pedro Pérez-Segura, Silvia Sánchez-Ramón
Publikováno v:
Diagnostics, Vol 11, Iss 4, p 678 (2021)
Early detection of SARS-CoV-2 is essential for a timely update of health policies and allocation of resources. Particularly, serological testing may allow individuals with low-risk of being contagious of SARS-CoV-2 to return to daily activities. Both
Externí odkaz:
https://doaj.org/article/28f9df4ac8434f9ea27f9886f9a6f16d
Autor:
Ana María Pello Lázaro, Carmen Cristóbal, Juan Antonio Franco-Peláez, Nieves Tarín, Álvaro Aceña, Rocío Carda, Ana Huelmos, María Luisa Martín-Mariscal, Jesús Fuentes-Antras, Juan Martínez-Millá, Joaquín Alonso, Óscar Lorenzo, Jesús Egido, Lorenzo López-Bescós, José Tuñón
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0169826 (2017)
Proton-pump inhibitors (PPIs) seem to increase the incidence of cardiovascular events in patients with coronary artery disease (CAD), mainly in those using clopidogrel. We analysed the impact of PPIs on the prognosis of patients with stable CAD.We fo
Externí odkaz:
https://doaj.org/article/029ab48ee7fa4256907559f235b569f2
Autor:
Silvia Sánchez-Ramón, MD, PhD, Jesús Fuentes-Antrás, MD, Nicholas L. Rider, MD, Pedro Pérez-Segura, MD, PhD, Eduardo de la Fuente-Muñoz, MD, Miguel Fernández-Arquero, PhD, Esmeralda Neves, MD, Rebeca Pérez de Diego, PhD, Alberto Ocaña, MD, PhD, Kissy Guevara-Hoyer, MD, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 2, Pp 100203- (2024)
Background: Gastric cancer (GC) stands as a prominent cause of cancer-related mortality and ranks second among the most frequently diagnosed malignancies in individuals with common variable immunodeficiency (CVID). Objective: We sought to conduct a c
Externí odkaz:
https://doaj.org/article/999d1c18df1e4ce0b69c419d841eeff7
Autor:
José Tuñón, Álvaro Aceña, Ana Pello, Sergio Ramos-Cillán, Juan Martínez-Milla, Óscar González-Lorenzo, Jesús Fuentes-Antras, Nieves Tarín, Carmen Cristóbal, Luis Miguel Blanco-Colio, José Luis Martín-Ventura, Ana Huelmos, Carlos Gutiérrez-Landaluce, Marta López-Castillo, Joaquín Alonso, Lorenzo López-Bescós, Luis Alonso-Pulpón, Jesús Egido, Ignacio Mahíllo-Fernández, Óscar Lorenzo
Background N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels are increased in patients with cancer. In this paper we test whether NT-proBNP may identify patients who are going to receive a future cancer diagnosis (CD) in the short te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2abbb09106ed7a1f0d5d9427e67823af
https://doi.org/10.21203/rs.3.rs-135088/v1
https://doi.org/10.21203/rs.3.rs-135088/v1
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 1, Pp n/a-n/a (2024)
Abstract Breast cancer arises from a series of molecular alterations that disrupt cell cycle checkpoints, leading to aberrant cell proliferation and genomic instability. Targeted pharmacological inhibition of cell cycle regulators has long been consi
Externí odkaz:
https://doaj.org/article/03bb5f328ae6495b81eedd820a3bcf93
Autor:
Rocío Carda, Oscar Lorenzo, Ana Maria Pello, Álvaro Aceña, Carlos Gutierrez Landaluce, Carmen Cristobal, Nieves Tarín, Ana Huelmos, Jesús Fuentes-Antras, María Martín Mariscal, Ignacio Hernandez Gonzalez, Lorenzo Lopez Bescos, José Tunon
Publikováno v:
Journal of the American College of Cardiology. 71:A125
The use of high-sensitive troponin I (hsTnI) in clinical practice is currently limited to the context of the acute coronary syndrome. In stable coronary artery disease (SCAD), its clinical value is not clear. We studied 989 patients with SCAD. At bas